Stanley Marks

Dr. Stanley Marks

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2011 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
SMStanley Marks
Stanley Marks
SRS.C. Rankin
S.C. Rankin
BBB.A. Byrne
B.A. Byrne
JWJ.S. Weese
J.S. Weese
This report offers a consensus opinion on the diagnosis, epidemiology, treatment, and control of the primary enteropathogenic bacteria in dogs and cats, with an emphasis on Clostridium difficile, Clostridium perfringens, Campylobacter spp., Salmonella spp., and Escherichia coli associated with granulomatous colitis in Boxers. Veterinarians are challenged when attempting to diagnose animals with suspected bacterial-associated diarrhea because well-scrutinized practice guidelines that provide objective recommendations for implementing fecal testing are lacking. This problem is compounded by similar isolation rates for putative bacterial enteropathogens in animals with and without diarrhea, and by the lack of consensus among veterinary diagnostic laboratories as to which diagnostic assays should be utilized. Most bacterial enteropathogens are associated with self-limiting diarrhea, and injudicious administration of antimicrobials could be more harmful than beneficial. Salmonella and Campylobacter are well-documented zoonoses, but antimicrobial administration is not routinely advocated in uncomplicated cases and supportive therapy is recommended. Basic practices of isolation, use of appropriate protective equipment, and proper cleaning and disinfection are the mainstays of control. Handwashing with soap and water is preferred over use of alcohol-based hand sanitizers because spores of C. difficile and C. perfringens are alcohol-resistant, but susceptible to bleach (1 : 10 to 1 : 20 dilution of regular household bleach) and accelerated hydrogen peroxide. The implementation of practice guidelines in combination with the integration of validated molecular-based testing and conventional testing is pivotal if we are to optimize the identification and management of enteropathogenic bacteria in dogs and cats.

31 October 2018 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
SMStanley Marks
Stanley Marks
PKPeter Hendrik Kook
Peter Hendrik Kook
MPMark G. G. Papich
Mark G. G. Papich
MTM. Katherine Tolbert
M. Katherine Tolbert
MWMichael D. Willard
Michael D. Willard
The gastrointestinal (GI) mucosal barrier is continuously exposed to noxious toxins, reactive oxygen species, microbes, and drugs, leading to the development of inflammatory, erosive, and ultimately ulcerative lesions. This report offers a consensus opinion on the rational administration of GI protectants to dogs and cats, with an emphasis on proton pump inhibitors (PPIs), histamine type‐2 receptor antagonists (H2RAs), misoprostol, and sucralfate. These medications decrease gastric acidity or promote mucosal protective mechanisms, transforming the management of dyspepsia, peptic ulceration, and gastroesophageal reflux disease. In contrast to guidelines that have been established in people for the optimal treatment of gastroduodenal ulcers and gastroesophageal reflux disease, effective clinical dosages of antisecretory drugs have not been well established in the dog and cat to date. Similar to the situation in human medicine, practice of inappropriate prescription of acid suppressants is also commonplace in veterinary medicine. This report challenges the dogma and clinical practice of administering GI protectants for the routine management of gastritis, pancreatitis, hepatic disease, and renal disease in dogs and cats lacking additional risk factors for ulceration or concerns for GI bleeding. Judicious use of acid suppressants is warranted considering recent studies that have documented adverse effects of long‐term supplementation of PPIs in people and animals. Consensus Statement Consensus Statements of the American College of Veterinary Internal Medicine (ACVIM) provide the veterinary community with up‐to‐date information on the pathophysiology, diagnosis, and treatment of clinically important animal diseases. The ACVIM Board of Regents oversees selection of relevant topics, identification of panel members with the expertise to draft the statements, and other aspects of assuring the integrity of the process. The statements are derived from evidence‐based medicine whenever possible and the panel offers interpretive comments when such evidence is inadequate or contradictory. A draft is prepared by the panel, followed by solicitation of input by the ACVIM membership that may be incorporated into the statement. It is then submitted to the Journal of Veterinary Internal Medicine, where it is edited before publication. The authors are solely responsible for the content of the statements.

1 November 2011 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Closed access
PDF file
STS. Trivedi
S. Trivedi
SMStanley Marks
Stanley Marks
PKP.H. Kass
P.H. Kass
JLJ.A. Luff
J.A. Luff
SKS.M. Keller
S.M. Keller
BMB. Murphy
B. Murphy

1 September 2002 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Closed access
PDF file
SMStanley Marks
Stanley Marks
EKElizabeth J. Kather
Elizabeth J. Kather
PKPhilip H. Kass
Philip H. Kass
AMAnn C. Melli
Ann C. Melli

1 September 2007 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Closed access
PDF file
SMSumiko R. Mekaru
Sumiko R. Mekaru
SMStanley Marks
Stanley Marks
AFAllison J. Felley
Allison J. Felley
NCNadira Chouicha
Nadira Chouicha
PKPhilip H. Kass
Philip H. Kass

1 May 2012 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Closed access
PDF file
AZA.C. Zacuto
A.C. Zacuto
SMStanley Marks
Stanley Marks
JOJ. Osborn
J. Osborn
KDK.L. Douthitt
K.L. Douthitt
KHK.L. Hollingshead
K.L. Hollingshead
PBP.C. Belafsky
P.C. Belafsky